Post by Sandoz
1,159,253 followers
The potential of off-patent medicines requires coordinated action to be unlocked 🤝 This was a key takeaway from our Chief Scientific Officer Claire D'Abreu-Hayling’s discussion with Reuters Events Pharma. Opportunities to ensure sustainable access go beyond scientific progress. It depends on the resilient development, manufacturing, and supply of medicines, alongside an ecosystem that supports both development and uptake. At Sandoz, we will continue to advocate for an ecosystem that supports off-patent medicine adoption. Building on our 140-year heritage, we remain committed to investing in and expanding our capabilities to deliver high-quality, affordable medicines to patients globally. Watch Claire’s full interview: https://lnkd.in/efW_Qbkx
Video Content